The pharmacy residency in oncology builds on experiences in the PGY1 year and is designed to provide a well-rounded experience leading to the development of expert knowledge, skills, and clinical leadership in the practice of oncology pharmacy. This 12-month program offers training opportunities through a variety of clinical rotations and interactions with multidisciplinary healthcare teams. We offer a flexible program that focuses on the goals of the resident and is intended to provide clinical, research, and teaching experience. Graduates of the program should be prepared to pursue employment as a hematology/oncology pharmacotherapy clinical specialist in the acute care setting, as well as demonstrate competency in written and oral communication, and oncology research.
The program emphasizes clinical practice with required rotations in leukemia, lymphoma, stem cell transplant, solid tumors, ambulatory oncology, investigational drug services, palliative care, and chemotherapy preparation. Elective rotations may be completed in any of the required rotations for an additional five weeks. Additional elective rotations include pediatric oncology and infectious diseases. Along with excellence in clinical care, NewYork-Presbyterian is committed to ongoing oncology research. Residents will have broad exposure to investigator-initiated research studies as well as ongoing Phase 1, 2, and 3 clinical trials in a wide range of malignancies.
Additional learning experiences include completion of a medication usage evaluation (MUE) and research project. Residents also participate in the Hematology/Oncology Subcommittee. The resident will develop teaching skills by providing in-service presentations to pharmacy staff and other health care providers, precepting PGY1 residents and pharmacy students, leading case-based clinical discussions, and critically evaluating literature.
This residency participates in the American Society of Health-System Pharmacists Residency Matching Program and is fully accredited by ASHP.
- Adult Leukemia (5 weeks)
- Adult Lymphoma (5 weeks)
- Adult Stem Cell Transplant (5 weeks)
- Solid Tumor Outpatient Clinic (5 weeks)
- Hematologic Malignancy Outpatient Clinic (5 weeks)
- Inpatient Solid Tumors (5 weeks)
- Investigational Drug Services (2 weeks)
- Palliative Care (2 weeks)
Elective Rotations (2 electives, 5 weeks)
- Pediatric Oncology (5 weeks)
- Transplant Infectious Diseases (5 weeks)
- Any required rotation may be repeated as an advanced elective
- Peter Campbell, PharmD, BCOP
- Rachel Abramova, PharmD, BCOP
- Syed Arafath, PharmD, BCOP
- Jessica Baron, PharmD, BCOP
- Lillian, Chou, PharmD, BCOP
- Ibis Lopez, PharmD, BCPS
- Michelle Nguyen, PharmD, BCOP
- Michelle Pasciolla, PharmD, BCOP
- Khilna Patel, PharmD, MBA, BCOP
- Jennifer Santamala, PharmD, BCOP
- Drew Seidel, PharmD
Compensation and Benefits
Residents earn an annual stipend of $53,000 Paid time off is allotted for vacation/personal time, holidays, interviews, and professional meetings. Additional benefits include travel stipend for professional meetings, comprehensive health insurance, and subsidized housing (pending availability).
This residency program participates in the American Society of Health-System Pharmacists (ASHP) Residency Matching Program and is fully-accredited by ASHP.
PGY2 oncology pharmacy residents work on-site at the Weill Cornell Medical Center campus every third weekend. Residents provide clinical coverage on Saturdays and oncology pharmacy satellite coverage on Sundays. Duties may include, but are not limited to:
- Pharmacy satellite operations
- Drug information coverage
- Chemotherapy admixture
For more information on the requirements for submitting an application to our program, please visit our To Apply page.
Peter Campbell, PharmD, BCOP
Program Director, PGY2 Hematology/Oncology
Department of Pharmacy